NOTCH1 and rhabdomyosarcoma: Our results are particularly important, as NOTCH1 inhibitory antibodies are now being assessed in preclinical models that have increased specificity and less gastrointestinal toxicity as pan-g-secretase inhibitors (Wu et al., 2010), raising hope that these strategies might be applied to the treatment of rhabdomyosarcoma in the future.